title: On-line hemodiafiltration in Southeast Asia: a three-year prospective study of a single center.
abstract: Growing evidence suggests the superiority of on-line hemodiafiltration (HDF) compared with the conventional hemodialysis technique in many aspects; however, on-line HDF is still not used worldwide, including in Southeast Asia. The purpose of this study is to compare various clinical outcomes between on-line HDF and high-flux hemodialysis (HFHD). This was a single-center three-year prospective observational study that demonstrated the clinical parameters after switching from HFHD to on-line HDF in 22 HDF patients, whose average age was 58.1 +/- 13.3 years. The incidence of intradialytic undesired events, including hypotension, decreased and an apparent increase in appetite and an improvement in overall well-being were recorded by most patients after switching to on-line HDF. The data for dry weight, body mass index, and normalized protein nitrogen appearance, which represent nutritional status, showed a significant improvement while still maintaining a satisfactory albumin level. The adequacy in terms of urea reduction ratio significantly increased. The serum predialysis beta(2)-microglobulin levels were reduced by 25.7% from 31.1 +/- 3.1 to 23.1 +/- 4.8 mg/L (P < 0.05) at six months and remained constant during the three years of follow-up. The patients' lipid profile was well controlled, and the mean C-reactive protein value was still maintained in the normal range. In conclusion, our three-year experience showed that on-line HDF is a well-tolerated treatment with a lower incidence of intradialytic undesired events. The potential benefits may include the effective removal of higher molecular weight uremic toxins and an improved nutritional status, along with a low inflammatory state.
authors.affiliation: Division of Nephrology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Khajohn
authors.initials: K
authors.lastname: Tiranathanagul
authors.forename: Kearkiat
authors.initials: K
authors.lastname: Praditpornsilpa
authors.forename: Pisut
authors.initials: P
authors.lastname: Katavetin
authors.forename: Nattachai
authors.initials: N
authors.lastname: Srisawat
authors.forename: Natavudh
authors.initials: N
authors.lastname: Townamchai
authors.forename: Paweena
authors.initials: P
authors.lastname: Susantitaphong
authors.forename: Kriang
authors.initials: K
authors.lastname: Tungsanga
authors.forename: Somchai
authors.initials: S
authors.lastname: Eiam-Ong
mesh_terms: D000328:Adult; D000368:Aged; D001210:Asia, Southeastern; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D017583:Hemodiafiltration / Q000379:methods*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D011446:Prospective Studies; D012709:Serum Albumin / Q000378:metabolism; D016896:Treatment Outcome; D014508:Urea / Q000378:metabolism; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D012709:Serum Albumin; D001613:beta 2-Microglobulin; D014508:Urea; D002097:C-Reactive Protein